Biogen
BIIB
Market cap $27.1B

185.76 USD

+3.46

1.90%

At close Oct 9, 4:00 PM EDT

After hours

185.76

+0.00

0.00%

1 day

1.90%

5 days

-0.77%

1 month

-6.78%

3 months

-18.90%

6 months

-10.05%

Year to date

-30.61%

1 year

-29.69%

5 years

-16.37%

About: Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.

Employees: 7,570

Healthcare Biological Products, Except Diagnostic Substances

0

Funds holding %

of 6,740 funds

0

Analysts bullish %

of 20 analysts

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

38% more funds holding in top 10

Funds holding in top 10: 8 [Q1] → 11 (+3) [Q2]

7% more capital invested

Capital invested by funds: $27.8B [Q1] → $29.7B (+$1.89B) [Q2]

0.71% less ownership

Funds ownership: 88.7% [Q1] → 87.98% (-0.71%) [Q2]

1% less funds holding

Funds holding: 927 [Q1] → 920 (-7) [Q2]

6% less repeat investments, than reductions

Existing positions increased: 311 | Existing positions reduced: 332

6% less first-time investments, than exits

New positions opened: 101 | Existing positions closed: 108

10% less call options, than puts

Call options by funds: $316M | Put options by funds: $353M

See Fund Rankings

Research analyst outlook

20 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$190

2%

upside

Avg. target

$265

43%

upside

High target

$313

68%

upside

20 analyst ratings

15 positive

75%

5 neutral

25%

0 negative

0%

RBC Capital Brian Abrahams 39% 1-year accuracy 30 / 77 met price target	45%upside $269	Outperform Maintained	4 Oct 2024
UBS Colin Bristow 20% 1-year accuracy 3 / 15 met price target	9%upside $202	Neutral Maintained	3 Oct 2024
Needham Ami Fadia 54% 1-year accuracy 61 / 112 met price target	53%upside $285	Buy Reiterated	24 Sept 2024
Wedbush Laura Chico 51% 1-year accuracy 36 / 70 met price target	10%upside $205	Neutral Maintained	23 Sept 2024
RBC Capital Brian Abrahams 39% 1-year accuracy 30 / 77 met price target	57%upside $292	Outperform Reiterated	19 Sept 2024

See Analyst Rankings

Financial journalist opinion

Based on 16 articles about BIIB published over the past 30 days

Biogen's stock bounces after FDA boost on kidney-transplant rejection treatment

Biogen stock was headed higher Wednesday, to bounce off an 11-year closing low, after the biotechnology company received positive news from regulators about its treatment for kidney-transplant rejections.

Biogen's stock bounces after FDA boost on kidney-transplant rejection treatment

Biogen Receives U.S. FDA Breakthrough Therapy Designation for Felzartamab for the Treatment of Antibody-Mediated Rejection in Kidney Transplant Recipients

CAMBRIDGE, Mass., Oct. 09, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) – Biogen announced today that felzartamab, an investigational anti-CD38 monoclonal antibody, has received Breakthrough Therapy Designation (BTD) from the U.S. Food and Drug Administration (FDA) for the treatment of late antibody-mediated rejection (AMR) without T-cell mediated rejection in kidney transplant patients. The FDA grants BTD to drug candidates for serious or life-threatening conditions and that have preliminary clinical evidence demonstrating potential to provide substantial improvement over existing therapies. The designation provides additional opportunities to engage the FDA and to support the drug development program through Fast Track designation features.

Biogen Receives U.S. FDA Breakthrough Therapy Designation for Felzartamab for the Treatment of Antibody-Mediated Rejection in Kidney Transplant Recipients

New Higher Dose Nusinersen Efficacy and Safety Data Presented at World Muscle Society Congress, Highlight Potential to Maximize Benefit of Nusinersen in SMA

CAMBRIDGE, Mass., Oct. 08, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced detailed results from Part B and Part C of the Phase 2/3 DEVOTE study evaluating the safety and efficacy of an investigational higher dose regimen of nusinersen in spinal muscular atrophy (SMA), showing benefits in both individuals previously treated and treatment-naïve to nusinersen with infantile-onset or later-onset SMA. The investigational, higher dose regimen of nusinersen comprises a more rapid loading regimen, two 50 mg doses 14 days apart, and higher maintenance regimen, 28 mg, every 4 months, compared to the approved nusinersen regimen (SPINRAZA®). Data to be presented during the World Muscle Society (WMS) 2024 Congress (Oct. 8-12, 2024 in Prague) highlight the potential of this investigational higher dose regimen to help address remaining unmet need in SMA.

New Higher Dose Nusinersen Efficacy and Safety Data Presented at World Muscle Society Congress, Highlight Potential to Maximize Benefit of Nusinersen in SMA

Zacks Investment Research

Why Biogen Inc. (BIIB) is a Top Value Stock for the Long-Term

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Why Biogen Inc. (BIIB) is a Top Value Stock for the Long-Term

Zacks Investment Research

SAGE, BIIB End Collaboration for Neurology Candidate SAGE-324

Sage Therapeutics announces discontinuation of the collaboration agreement with Biogen related to SAGE-324 for essential tremor.

SAGE, BIIB End Collaboration for Neurology Candidate SAGE-324

Zacks Investment Research

Biogen's Lupus Candidate Meets Key Goals in Phase III Study

The phase III PHOENYCS GO study evaluating BIIB and UCB's drug candidate, dapirolizumab pegol, for treating systemic lupus erythematosus meets the primary endpoint.

Biogen's Lupus Candidate Meets Key Goals in Phase III Study

Biogen and Belgian partner UCB announce positive data from late-stage trial of lupus treatment

Biogen Inc.'s stock rose 2% early Tuesday, after the company and Belgian partner UCB announced positive results in a late-stage trial

Biogen and Belgian partner UCB announce positive data from late-stage trial of lupus treatment

Biogen-UCB's lupus drug meets main goal of late-stage trial

Biogen and Belgian partner UCB said on Tuesday their experimental lupus treatment met the main goal of a late-stage trial in patients with the chronic disease, a surprise result after the drug failed an earlier mid-stage study.

Biogen-UCB's lupus drug meets main goal of late-stage trial

UCB and Biogen Announce Positive Topline Results From Phase 3 Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus and are Initiating Second Phase 3 Study in 2024

BRUSSELS and CAMBRIDGE, Mass., Sept. 24, 2024 (GLOBE NEWSWIRE) -- UCB (Euronext Brussels: UCB) and Biogen Inc. (NASDAQ: BIIB) today announced positive topline results from the Phase 3 PHOENYCS GO study evaluating dapirolizumab pegol, a novel Fc-free anti-CD40L drug candidate, in people living with moderate-to-severe systemic lupus erythematosus (SLE). Dapirolizumab pegol, in addition to standard-of-care (SOC) treatment, met the primary endpoint to demonstrate greater improvement of moderate-to-severe disease activity as assessed by achievement of British Isles Lupus Assessment Group (BILAG)-based Composite Lupus Assessment (BICLA) after 48 weeks versus placebo in addition to SOC. Clinical improvements were observed among key secondary endpoints measuring disease activity and flares.

UCB and Biogen Announce Positive Topline Results From Phase 3 Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus and are Initiating Second Phase 3 Study in 2024

Samsung Bioepis and Biogen Receive Positive CHMP Opinion for Aflibercept Biosimilar, OPUVIZ™

INCHEON, South Korea and CAMBRIDGE, Mass., Sept. 20, 2024 (GLOBE NEWSWIRE) -- Samsung Bioepis Co., Ltd. and Biogen Inc. (Nasdaq: BIIB) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for OPUVIZ™ 40 mg/mL solution for injection in a vial, a biosimilar referencing Eylea2 (aflibercept), also known as SB15.

Samsung Bioepis and Biogen Receive Positive CHMP Opinion for Aflibercept Biosimilar, OPUVIZ™

See News Rankings

Charts implemented using Lightweight Charts™